ReviewReviews in cardiovascular medicine2026
Protective Effects of Dexmedetomidine Against Ischemic Heart Disease and Diabetic Cardiomyopathy by Targeting Ferroptosis.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Ischemic heart disease and diabetic cardiomyopathy are two CVDs characterized by prominent myocardial injuries. Calcium overload, mitochondrial damage, the accumulation of reactive oxygen species (ROS), and abnormal programmed cell death (PCD) pathways, such as autophagy, pyroptosis, apoptosis, and ferroptosis, are recognized as the major mechanisms of myocardial injury. Dexmedetomidine (DEX) is a selective α2-adrenergic receptor agonist that is often administered to surgical patients due to the associated sedative, analgesic, and anxiolytic properties. Recent studies have indicated that DEX can exhibit more beneficial effects in patients, including reducing myocardial and vascular damage in CVD patients. Mechanistically, DEX reduces levels of oxidative stress markers and inflammatory cytokines and improves mitochondrial function. Numerous studies have revealed novel regulatory roles for DEX in mediating ferroptosis. This study summarizes the expression and functions of ferroptosis in ischemic heart disease and diabetic cardiomyopathy and discusses the regulatory mechanism of DEX in ferroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.